Abstract

Nuclear hormone receptors can be considered the first precision oncology targets. To date, therapeutics designed to interfere with androgen receptor (AR) signaling remain the main treatment approach for advanced prostate cancer. While dramatic responses are observed, reactivation of AR signaling at disease progression is a nearly universal occurrence. This presentation will discuss the molecular events that underlie resurrection of the AR program in advanced prostate cancer with an orientation toward new treatment strategies.